182 Results Found

Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1

Collaboration with the Bill & Melinda Gates Foundation Seeks to Bring Forward a New HIV Prevention Option to Help Address the HIV Epidemic with Focus on Women in Sub-Saharan Africa Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced a collaboration with the Bill & Melinda Gates Foundation (the foundation) where the foundation is committing to provide funding to support a pivotal Phase 3 study investigating a once-monthly oral pre-exposure prophylaxis (PrEP) 1 option in women and adolescent girls at high risk for acquiring HIV-1 infection in sub-Saharan Africa. The study, IMPOWER 22, will evaluate the efficacy and safety of islatravir - Merck’s novel investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI) under evaluation for both treatment and prevention - and is anticipated to begin by early 2021. More than half of new HIV infections globally occur in sub-Saharan Africa, with women accounting for nearly 60 percent

Merck publishes 2019/2020 corporate responsibility report

Dear Stakeholders, As we launch our 2019/2020 Corporate Responsibility Report, the world continues to face a health crisis of proportions unprecedented in our lifetimes. With the COVID-19 pandemic persisting in communities across the globe, never has there been a moment when our mission—to save and improve lives—appears as clear and compelling. For more than 125 […]

search result image

Merck and Instituto Butantan Announce Collaboration Agreement to Develop Vaccines to Protect Against Dengue Infections

Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Instituto Butantan, Sao Paulo, Brazil, a non-profit producer of immunobiologic products for Brazil today announced a collaboration agreement to develop vaccines to protect against dengue virus disease, the mosquito-borne infection. Instituto Butantan and Merck have licensed certain rights from National Institute of Allergy and Infectious Diseases (NIAID), part of the United States National Institutes of Health (NIH), for the development of live attenuated tetravalent vaccines (LATV). Instituto Butantan’s dengue vaccine candidate, TV003, is currently being evaluated in a large Phase 3 study in Brazil. “By sharing data from our ongoing vaccine development programs, Instituto Butantan and Merck are better positioned to achieve our goal of reducing the significant human and economic toll of dengue virus in Brazil and around the world,” said Dr. Dimas Covas, director, Instituto Butantan. “We look forward to

Merck Announces Fourth-Quarter and Full-Year 2020 Financial Results

Fourth-Quarter 2020 Worldwide Sales Were $12.5 Billion, an Increase of 5% Fourth-Quarter 2020 GAAP Loss per Share Was $0.83, Reflecting Charges Related to Acquisitions and Intangible Asset Impairments; Fourth-Quarter Non-GAAP EPS Was $1.32 Full-Year 2020 Worldwide Sales Were $48.0 Billion, an Increase of 2%; Excluding the Impact from Foreign Exchange, Sales Grew 4% KEYTRUDA 2020 Worldwide Sales Grew 30% to $14.4 Billion BRIDION 2020 Worldwide Sales Grew 6% to $1.2 Billion; Excluding the Impact from Foreign Exchange, Sales Grew 7% Animal Health 2020 Worldwide Sales Grew 7% to $4.7 Billion; Excluding the Impact from Foreign Exchange, Sales Grew 10% Full-Year 2020 GAAP EPS Was $2.78, Reflecting Charges Related to Acquisitions, Collaborations and Intangible Asset Impairments; Full-Year Non-GAAP EPS Was $5.94 2021 Financial Outlook Anticipates Full-Year 2021 Worldwide Sales to Be Between $51.8 Billion and $53.8 Billion, Including a Positive Impact from Foreign Exchange of Approximately 2%

Merck Commemorates 30 Years of MECTIZAN® Donation Program Progress

Program Expanded to Reach Additional 100 Million People Annually for Lymphatic Filariasis in Support of New, Evidence-Based WHO Guidelines Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced an expansion of the MECTIZAN® Donation Program (MDP) to reach up to an additional 100 million people per year through 2025 as part of the global effort to eliminate lymphatic filariasis (LF). Through the MDP, established by Merck in 1987, Merck donates MECTIZAN ® (ivermectin) for onchocerciasis (river blindness) in all affected areas (Latin America, Africa, Yemen) and for LF in African countries where it co-exists with river blindness. LF, also known as elephantiasis, is a parasitic disease transmitted to humans through the bites of mosquitoes. Over time, infection can impair the lymphatic system leading to severe swelling of the limbs and genitals resulting in severe disability and social stigma. One of the neglected tropical diseases (NTDs), it is present in 72

Moderna and Merck Expand mRNA Cancer Vaccines Collaboration

Expansion Includes the Joint Development of Moderna’s KRAS Oncogene Program and Other Potential mRNA Cancer Vaccines; Merck to Make Equity Investment in Moderna CAMBRIDGE, Mass. and KENILWORTH N.J. May 3, 2018 — Moderna Therapeutics and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced an expansion of their 2016 collaboration to develop and commercialize novel personalized messenger RNA (mRNA) cancer vaccines to now include shared antigen mRNA cancer vaccines including mRNA-5671, Moderna’s mRNA KRAS cancer vaccine. Moderna developed mRNA-5671 starting in 2017.  The two companies will now advance jointly mRNA-5671 in human studies, and plan to conduct combination studies with additional immuno-oncology therapies. “Augmentation of immune responses offers great promise in cancer therapy, as our work with the PD-1-specific antibody KEYTRUDA has shown,” said Dr. Roger M. Perlmutter, President, Merck Research Laboratories.  “We now look

MSD for Mothers Commits $10 Million and Business Expertise to the Global Financing Facility to Help End Preventable Deaths of Mothers

Represents a Critical Step toward Meeting the Sustainable Development Goals for Women, Children and Adolescent Health MSD, known as Merck & Co., Inc., Kenilworth, N.J., U.S.A., inside the United States and Canada, announced today its $10 million commitment to the Global Financing Facility (GFF) in support of Every Woman Every Child to improve maternal and child health in low- and lower-middle-income countries worldwide through its MSD for Mothers initiative. Through the GFF – a multi-stakeholder partnership hosted by the World Bank Group – countries are aiming to make a much greater impact on the lives of their most vulnerable citizens, with the goal of preventing an estimated 3.8 million maternal deaths, 101 million child deaths and 21 million stillbirths by 2030. “Women are the cornerstone of a healthy and prosperous world. When a woman survives pregnancy and childbirth, her family, community and nation thrive,” said Kenneth C. Frazier, chairman and chief executive officer, MSD.

Merck Announces First Nine “Safer Childbirth Cities” Committed to Reducing Maternal Deaths and Narrowing Disparities in the US

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today its funding support of projects in nine cities across the country to help end preventable maternal deaths. Each project will be tailored to the needs of pregnant women in their respective city, focusing on reducing barriers to prenatal and postpartum care and addressing both the health and social factors that affect a healthy pregnancy and childbirth. The vision for the Safer Childbirth Cities Initiative is to foster local solutions that help cities become safer – and more equitable – places to give birth. It is part of Merck for Mothers , Merck’s global initiative to help end preventable deaths of women from complications related to pregnancy and childbirth. For the inaugural class, Safer Childbirth Cities will also be co-funded with the Burke Foundation, The Nicholson Foundation, the Community Health Acceleration Partnership, the W.K. Kellogg Foundation, Rhia Ventures, and others. “Safer Childbirth

Merck Foundation Announces Grant to American Cancer Society to Improve Access to Cancer Care in Resource-Limited Settings

The Merck Foundation (the Foundation) and the American Cancer Society (ACS) announced today that the Foundation awarded a $1.99 million, five-year grant to ACS to improve support and access to care for people living with cancer in low-and-middle-income countries, particularly in sub-Saharan Africa. This funding will help ACS further develop its capacity development approach to expanding patient navigation to countries with a growing burden of cancer. More than 70% of the 9 million cancer-related deaths worldwide are in resource-limited settings, where patients face many barriers in seeking a timely diagnosis and receiving high-quality cancer care. Patient navigators—whether nurses providing cancer education or lay health workers linking patients to transportation services in the community—play a vital role in supporting patients from the point of diagnosis at a health facility through their treatment journey. With support from the Foundation, ACS will fortify its patient navigation

1-10 of 182